Company News

Company News
December 08, 2023
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
Vancouver, British Columbia, Canada – December 8, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
December 01, 2023
Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
Vancouver, British Columbia, Canada – December 1, 2023 – Core One Labs Inc. (“Core One” or the “Company”) (CSE: COOL), (OTCQB: CLABF),...
Read more
Company News
September 18, 2023
Core One Labs Closes Non-Brokered Private Placement
Vancouver, British Columbia, Canada – September 18, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt:...
Read more
Company News
September 11, 2023
Core One Labs Announces Non-Brokered Private Placement
Vancouver, British Columbia, Canada – September 11, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt:...
Read more
Company News
August 23, 2023
Core One Labs Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions
Vancouver, British Columbia, Canada – August 23, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
August 04, 2023
Core One’s Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson’s Disease
Vancouver, British Columbia, Canada – August 4, 2023 – Core One Labs Inc. (CSE: COOL) (OTCQB: CLABF) (Frankfurt: LD6, WKN: A3CSSU), (the “Company”...
Read more